The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Simvastatin plus capecitabine-cisplatin (XP) versus placebo plus capecitabine-cisplatin (XP) in patients with previously untreated advanced gastric cancer: A double-blind randomized phase 3 study.
Seung Kim
No relevant relationships to disclose
Won Ki Kang
No relevant relationships to disclose
Jeeyun Lee
No relevant relationships to disclose
Se Hoon Park
No relevant relationships to disclose
Joon Oh Park
No relevant relationships to disclose
Young Suk Park
No relevant relationships to disclose
Ho Yeong Lim
No relevant relationships to disclose
Jung Hun Kang
No relevant relationships to disclose
In Gyu Hwang
No relevant relationships to disclose
Sang-Cheol Lee
No relevant relationships to disclose
Keon-Woo Park
No relevant relationships to disclose
Hyo Rak Lee
No relevant relationships to disclose